Abstract Library

#4599 Endosonography guided coloenterostomy for management of malignant small bowel ileus

Introduction: Small-bowel ileus (SBI) is often decisive for the prognosis in midgut neuroendocrine tumours (NET) and other peritoneally metastasised neoplasias. Conventional procedures of palliative care deliver unsatisfying results.

Conference:

Presenting Author: Weich A

Authors: Weich A, Retzbach L, Hartung V, Brand M, Kudlich T,

Keywords: Coloenterostomy, Endosonography, small bowel ileus, peritoneal carcinomatosis, midgut NET,

#4555 Assessment of gastric mucosa conditions changes in patients with gastric neuroendocrine neoplasia type 1 during gastroprotective therapy

Introduction: Currently, the incidence of gastric neuroendocrine neoplasia (gNEN) has increased significantly. Most gNEN are developed on the background of chronic atrophic gastritis (about 90%). Despite this, the role of chronic atrophic gastritis treatment (gastroprotective therapy) in dynamic of gNEN remains unexplored.

Conference:

Presenting Author: Konyakhina A

Authors: Konyakhina A, Feidorov I, Salimgereeva D, Petrova A,

Keywords: gNEN, atrophic gastritis, OLGA, rebamipide,

#4550 The relationship between MEN1 germline mutations and SSTR2 expression in neuroendocrine tumours

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary disease characterised by the development of multiglandular parathyroid disease, pituitary tumours, and duodenopancreatic neuroendocrine tumours (NETs). Germline mutations in the tumour suppressor gene MEN1 are the underlying cause. Somatostatin receptor 2 (SSTR2) is commonly expressed by NETs. However, the expression of SSTR2 in patients with MEN1 remains unclear.

Conference:

Presenting Author: Chi Y

Authors: Sun Y, Tan H, Wang H, Shi S, Dong L,

Keywords: multiple endocrine neoplasia type 1, somatostatin receptor 2, neuroendocrine tumour,

#4503 Duodenopancreatic neuroendocrine tumour in MEN1: Gender difference and survival rates

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is the most common inherited syndrome associated with NET development and metastatic duodenal-pancreatic (DP) NET is the main cause of death.

Conference:

Presenting Author: Liccardi A

Authors: Liccardi A, Roberto M, Cannavale G, Benevento E, Di Iasi G,

Keywords: Multiple endocrine neoplasia type 1, neuroendocrine tumour, gender difference, survival,

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,